摘要
[目的]探讨雌激素调节蛋白(PS2)在乳腺浸润性导管癌中的表达及其与临床病理因素间的关系。[方法]采用免疫组化方法检测155例乳腺浸润性导管癌中ER、PR和PS2的表达。[结果]全组PS2表达阳性率38.1%。在ER阳性和阴性病例中,PS2阳性率分别为48.6%和29.4%(χ2=5.977,P<0.05);在PR阳性和阴性组中,PS2阳性率分别为50.8%和28.9%(χ2=7.664,P<0.01)。PS2的表达与病人年龄、月经状况、肿瘤大小无关(P>0.05);而与腋淋巴结状况(P<0.001)、临床分期(P<0.05)有关。此外,PS2的表达在民族间也存在一定差异,但无统计学意义。[结论]乳腺浸润性导管癌中PS2的表达与ER、PR呈正相关关系,并与腋淋巴结状况和临床分期有关。PS2可以作为预测乳腺癌预后的一项重要指标。
To investigate the expression of estrogen-induced protein PS2 in infiltrating ductal breast carcinoma and the relationship with clinicopathological parameters. The expression of estrogen receptor (ER), progesterone receptor (PR) and PS2 in 155 cases with infiltrating ductal breast carcinoma were detected by the immunohistochemical technique(S-P). The positive expression of PS2 was found in 38.1% cases with infiltrating ductal breast carcinoma. The expression of PS2 was 48.6% in ER positive cases and 29.4% in ER negative cases(χ2=5.977, P<0.05). The positive expression of PS2 was 50.8% in PR positive cases and 28.9% in PR negative cases(χ2=7.664, P<0.01). The positive expression of PS2 was not correlated with patient's age, menopausal status, tumor size (P>0.05), but its expression was realated to the status of axillary lymph node(P<0.001) and clinical stage (P<0.05). PS2 expression among different nationalities showed little difference, but no statistical significance. [Conclusion] The expression of PS2 in infiltrating ductal breast carcinoma is positively correlated with ER and PR, and its expression is also related to the status of axillary lymph node and clinical stage. PS2 may be used as an important marker for prognosis and endocrine treatment in breast cancer.
出处
《肿瘤学杂志》
CAS
2005年第2期109-112,共4页
Journal of Chinese Oncology
关键词
乳腺肿瘤
癌
浸润性导管
雌激素受体调节剂
PS2基因
breast neoplasms
carcinoma, infiltrating duct
estrogen receptor modulators
PS2, gene
